Differential Calcium Leucovorin Protection of Human Lymphoid Cell Lines from Methotrexate

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1985 Jan 1

PMID 2410158

Citations 1

Authors

G P Browman

L Booker

P SPIEGL

Affiliations

Soon will be listed here.

Abstract

Human lymphoid cell lines were studied for leucovorin requirements to protect from methotrexate (MTX)-induced growth suppression. Over a 72h continuous exposure leucovorin provided better protection to the cell lines LAZ-007 and RAJI than to the cell lines CCRF-CEM and MOLT-4. The lower leucovorin requirement for LAZ-007 protection versus CCRF-CEM was also seen over a 3h exposure period in which leucovorin protection was assessed by measuring its effect on MTX-induced suppression of 3H-deoxyuridine incorporation into acid-precipitable material. Growth experiments with addition of hypoxanthine or thymidine did not abolish differential protection, suggesting that the phenomenon is not related to selective differences in the tolerance of these cells to an MTX-induced purineless or thymineless state. Preloading of cells with calcium leucovorin caused an identical shift of the CCRF-CEM and LAZ-007 MTX dose - response curves, suggesting that differential catabolism of leucovorin does not contribute to differential protection. The same degree of differential protection was observed for 5-methyltetrahydrofolate as for leucovorin, suggesting that differences in the metabolism of leucovorin do not contribute to differential protection. To elucidate the mechanism of differential protection the influence of leucovorin on [3H]MTX transport and polyglutamylation were studied. Although the Km(MTX) influx and the Ki(leucovorin) for MTX uptake were lower in CCRF-CEM compared with LAZ-007 cells, the size of the difference does not seem adequate to explain differential protection. The extent of MTX polyglutamylation in CCRF-CEM and LAZ-007 cells was identical and the influence of leucovorin on MTX polyglutamylation was the same in both cell lines.

Citing Articles

Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines.

Browman G, SPIEGL P, Booker L, Rosowsky A Cancer Chemother Pharmacol. 1985; 15(2):111-4.

PMID: 3874720 DOI: 10.1007/BF00257519.

References

Browman G . Comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines. Cancer Treat Rep. 1982; 66(12):2051-9. View

Sirotnak F, Donsbach R, Dorick D, Moccio D . Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models. Cancer Res. 1976; 36(12):4672-8. View

Rosenblatt D, Whitehead V, Matiaszuk N, Pottier A, Vuchich M, Beaulieu D . Differential effects of folinic acid and glycine, adenosine, and thymidine as rescue agents in methotrexate-treated human cells in relation to the accumulation of methotrexate polyglutamates. Mol Pharmacol. 1982; 21(3):718-22. View

McGuire J, Bertino J . Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem. 1981; 38 Spec No(Pt 1):19-48. DOI: 10.1007/BF00235686. View

Whitehead V, Perrault M, Stelcner S . Tissue-specific synthesis of methotrexate polyglutamates in the rat. Cancer Res. 1975; 35(11 Pt 1):2985-90. View

FRY D, Yalowich J, Goldman I . Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem. 1982; 257(4):1890-6. View

Dudman N, Slowiaczek P, Tattersall M . Methotrexate rescue by 5-methyltetrahydrofolate or 5-formyltetrahydrofolate in lymphoblast cell lines. Cancer Res. 1982; 42(2):502-7. View

Woods R, Fox R, Tattersall M . Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation. Br Med J (Clin Res Ed). 1981; 282(6264):600-2. PMC: 1504451. DOI: 10.1136/bmj.282.6264.600. View

Fisher R, Devita Jr V, Hubbard S, Longo D, Wesley R, Chabner B . Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983; 98(3):304-9. DOI: 10.7326/0003-4819-98-3-304. View

10.

Cadman E, Farber L, Berd D, BERTINO J . Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites. Cancer Treat Rep. 1977; 61(6):1109-16. View

11.

DeConti R, Schoenfeld D . A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer. 1981; 48(5):1061-72. DOI: 10.1002/1097-0142(19810901)48:5<1061::aid-cncr2820480502>3.0.co;2-x. View

12.

Stea B, Backlund Jr P, Berkey P, Cho A, HALPERN B, HALPERN R . Folate and pterin metabolism by cancer cells in culture. Cancer Res. 1978; 38(8):2378-84. View

13.

Halpern R, HALPERN B, Stea B, Dunlap A, Conklin K, Clark B . Pterin-6-aldehyde, a cancer cell catabolite: identification and application in diagnosis and treatment of human cancer. Proc Natl Acad Sci U S A. 1977; 74(2):587-91. PMC: 392336. DOI: 10.1073/pnas.74.2.587. View

14.

Clynes M, ONeill C . Folic acid degradation is not a property specific to cancer cells in culture. Cancer Lett. 1980; 10(2):133-40. DOI: 10.1016/0304-3835(80)90036-1. View

15.

FRY D, Anderson L, Borst M, Goldman I . Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res. 1983; 43(3):1087-92. View

16.

Schneider E, Stanbridge E, Epstein C . Incorporation of 3H-uridine and 3H-uracil into RNA: a simple technique for the detection of mycoplasma contamination of cultured cells. Exp Cell Res. 1974; 84(1):311-8. DOI: 10.1016/0014-4827(74)90411-x. View

17.

Browman G, SPIEGL P, Booker L, Rosowsky A . Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines. Cancer Chemother Pharmacol. 1985; 15(2):111-4. DOI: 10.1007/BF00257519. View

18.

Green D, Brecher M, Blumenson L, Grossi M, Freeman A . The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia. A comparison of three versus six courses. Cancer. 1982; 50(12):2722-7. DOI: 10.1002/1097-0142(19821215)50:12<2722::aid-cncr2820501204>3.0.co;2-t. View

19.

Bertino J . "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol. 1977; 4(2):203-16. View

20.

Moran R, Mulkins M, HEIDELBERGER C . Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. Proc Natl Acad Sci U S A. 1979; 76(11):5924-8. PMC: 411765. DOI: 10.1073/pnas.76.11.5924. View